Severe Asthma Masterclass, a local national virtual event held under the auspices of the Malaysian Thoracic Society, was conducted to provide a robust platform for an in-depth discussion on severe asthma management. This event was led by two renowned clinical experts in respiratory specialty, Associate Professor Dr Pang Yong Kek and Professor Norbert Berend who have vast experience in severe asthma management. Key topics on severe asthma prevalence, diagnosis, treatment and management, and role of eosinophils in the paradigm of severe asthma were presented and discussed during this event, providing a comprehensive overview on severe asthma management and the crucial role of biologics in treating severe eosinophilic asthma.
At the recent 18th Annual Scientific Meeting of the Malaysian Society of Haematology (MSH), Professor Dr Claire Harrison, clinical director at Guy’s and St Thomas’ NHS Foundation Trust, UK, presented an overview of myelofibrosis (MF) management considerations from a patient-centric perspective and the therapeutic role of ruxolitinib (Jakavi®, Novartis). The satellite symposium was organized by Novartis in collaboration with the MSH.
Even as the world grapples with recurring waves of SARS-CoV-2infection, the world’s endemic diseases—dengue being one of them—continue to proliferate in the background. The COVID-19 pandemic has overshadowed and redirected resources that would otherwise be used for United Nations’ Sustainable Developmental Goals 3. In this first interview of a series focused on dengue, Senior Consultant Infectious Disease Physician Dato’ Dr Mahiran Mustafa discussed the effects of movement control order on dengue cases, coinfection of dengue and COVID-19, and the management of dengue patients during the COVID -19 pandemic.
The respiratory tract is susceptible to infection because of its constant contact with the ambient air for gas exchange, and the mucosa overlying its surface is thin and moist. This is ideal for microbes to spread through the air in droplets, droplet nuclei and aerosols, and disperse quickly into the blood stream causing respiratory tract infections (RTIs), namely pneumococcal pneumonia, influenza, and pertussis. These RTIs are a burden to the health systems.
Dienogest is an oral progestin with selective 19-nortestosterone and progesterone activity that has been shown to be highly effective in the management of endometriosis. The Visanne Post-approval Observational Study(VIPOS) provided real-world evidence on the absence of serious adverse events with long-term use of dienogest for up to 7 years.
Pneumococcal disease (PD) is caused by Streptococcus pneumoniae, a gram-positive encapsulated diplococcus bacteria. Children with PD usually present with acute otitis media (AOM) though a small percentage, especially those ≤2 years old, may have invasive pneumococcal disease (IPD) such as bacteraemic pneumonia and/ or meningitis.
SMA is a neuromuscular disorder that causes progressive muscle weakness. It is an autosomal recessive disease where 95% of the cases is due to homozygous deletion of the SMN1 gene found in chromosome 5q11.2 to 5q13.3, while the remaining is due to point mutations.
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.